Key Developments: Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

5.30GBp
24 Dec 2014
Price Change (% chg)

0.00p (+0.00%)
Prev Close
5.30p
Open
5.30p
Day's High
--
Day's Low
--
Volume
4,015,531
Avg. Vol
2,692,177
52-wk High
5.60p
52-wk Low
1.77p

Search Stocks

Latest Key Developments (Source: Significant Developments)

Oxford Biomedica acquires Windrush Court Office
Monday, 13 Oct 2014 02:00am EDT 

Oxford Biomedica PLC:Says that it has acquired freehold of Windrush Court office and laboratory facilities in Transport Way, Oxford, England.Says for total cash consideration of 3.2 mln pounds from Oxford Real Estate Owner No. 2 Limited.Windrush Court, 6,684 sq m facility, is located directly opposite Oxford BioMedica's manufacturing facility and company intends to relocate its laboratories and office activities there in stages before current lease of Medawar Centre, Oxford expires in March 2016.The purchase of Windrush Court will enable company to consolidate its entire activities in Transport Way, improving operational effectiveness, and will also provide additional capacity to accommodate planned growth in business activities.As result of expected savings in rental costs and service charges, Oxford BioMedica expects to recover purchase cost within 4 years.  Full Article

Oxford Biomedica PLC announces second major agreement with Novartis
Friday, 10 Oct 2014 02:00am EDT 

Oxford Biomedica PLC:Signs further contracts with Novartis which build on collaboration with Novartis announced in May 2013.Under terms of new agreement, Novartis will pay $14 mln upfront including $4.3 mln equity subscription for non-exclusive worldwide development and commercialisation licence in oncology under Group's LentiVector platform.OXB will manufacture lentiviral vectors expressing CTL019/CART-019.Manufacturing contract has an initial three year term.Additionally, OXB has granted Novartis an exclusive licence for worldwide development and commercialisation of all Chimeric Antigen Receptor (CAR) T cell products arising from the process development collaboration.  Full Article

Oxford BioMedica plc announces fundraising and open offer; announces board change
Thursday, 29 May 2014 02:01am EDT 

Oxford BioMedica plc:Intends to raise gross proceeds of up to 25.7 mln pounds (23.7 mln pounds net of expenses) through a firm fundraising by means of a placing and subscriptions and an open offer at 2 pence per new ordinary share.Intended that 1,000,018,815 new ordinary shares will be issued through the firm fundraising to raise gross proceeds of 20.0 mln pounds.Up to 283,229,801 new ordinary shares will be issued through the open offer to raise up to a further 5.7 mln pounds gross.Charles Stanley & Co. Limited is acting as Sponsor, WG Partners LLP as Financial Adviser and Bookrunner.Roth Capital Partners as US Placing Agent to the Company.Proceeds of the fundraising will be used to continue to develop Oxford BioMedica's business based on its LentiVector platform, in particular to build on its growing ophthalmology portfolio.Says Nick Rodgers has informed the board of his intention to step down as Chairman of Oxford BioMedica when an appropriate replacement has been identified.  Full Article

Oxford Biomedica PLC Announces Loan Facility from Vulpes Life Sciences Fund
Tuesday, 19 Nov 2013 02:00am EST 

Oxford Biomedica PLC announced that the Company has signed a GBP 5 million secured loan facility agreement with its largest shareholder, the Vulpes Life Sciences Fund (Vulpes). The loan facility, which constitutes a related party transaction, is conditional upon shareholder approval pursuant to Listing Rule 11 of the Listing Rules of the UK Listing Authority. A circular convening a general meeting of shareholders will be published in due course.  Full Article

Oxford Biomedica PLC Receives Agreement From FDA And ANSM To Resume Recruitment Into Ocular Clinical Trials
Thursday, 17 Oct 2013 02:05am EDT 

Oxford Biomedica PLC announced that it has received agreement from the US Food and Drug Administration (FDA) and the French regulatory agency, ANSM, to resume recruitment into the RetinoStat Phase I, StarGen Phase I/IIa and UshStat Phase I/IIa studies using the existing clinical trial material.  Full Article

Oxford Biomedica PLC's TroVax Phase II Analyses Published In Immunotherapy-DJ
Monday, 29 Jul 2013 03:34am EDT 

Dow Jones reported that Oxford Biomedica PLC said that analyses of a TroVax Phase II study in patients with castration-resistant prostate cancer have been accepted for publication in the peer-reviewed medical journal Cancer Immunology, Immunotherapy. Phase II CRPC study: TroVax was well-tolerated in all patients; patients treated with TroVax plus docetaxel showed a greater median progression-free survival of 9.67 months compared with 5.10 months for patients on the docetaxel alone arm (P = 0.097; HR = 0.31; 95 % CI 0.08-1.24)(1). TroVax is a therapeutic cancer vaccine designed to stimulate the immune system to destroy cancerous cells expressing the 5T4 tumour antigen, which is broadly distributed throughout a wide range of solid tumours.  Full Article

BRIEF-Oxford Biomedica buys Windrush Court Office for 3.2 mln stg

* Oxford Biomedica has acquired freehold of Windrush Court Office and laboratory facilities in transport way, Oxford, England, for a total cash consideration of £3.2 million Source text for Eikon: Further company coverage:

Search Stocks